Windhover's Commentary

Deals in Depth: November 2009 (IN VIVO)

IN VIVO

In an alliance worth $849 million in pre-commercialization money, BMS added another rheumatoid arthritis therapeutic to its pipeline, Alder's Phase IIa ALD518. The top two pharma M&As were in the specialty pharmaceutical space--Biovitrum/Swedish Orphan and Enzon/Sigma-Tau. Meanwhile, Stryker got into the medical device reprocessing market via its acquisition of Ascent. And pharma and device financing were both down from the previous month (although October did boast several big outlier deals).

2009's Top Biopharma Dealmakers (IN VIVO)

IN VIVO

A flurry of dealmaking in December, especially by big pharmacos, helped to bring 2009 to a strong close in terms of alliances. But the year will probably most be remembered for the Big Pharma mega mergers that combined four major companies and topped the acquisitions list by their dollar values. We focus here on the dealmakers, showing which companies dominated the dealmaking landscape in terms of deal volume and value, as well as therapeutic categories that grabbed the most attention.

Novartis Eyes Full, $50 billion Alcon Takeover (IN VIVO)

IN VIVO

Novartis on Jan 4 announced it was exercising its option to purchase Nestl�'s remaining 52 percent stake in eye-care group Alcon for $28.1 billion. The Swiss Big Pharma will finish up paying almost $50 billion for full control of the group, given its controversial attempt to buy out the minority Alcon shareholders for a further $11.2 billion.

Sanofi Builds US-based Consumer Powerhouse in Preparation for Allegra OTC Switch (IN VIVO)

IN VIVO

Sanofi-Aventis' $1.8 billion bid for over-the-counter and personal care product firm Chattem Inc. offers the French firm a coveted toehold in the sizeable US consumer health care market while also opening potential opportunities in emerging markets. As such, the deal is in line with the French pharma's emphasis on diversification, helping the company hedge the development risks associated with its branded pharmaceuticals.

Remembering Donald Baim (IN VIVO)

IN VIVO

Among the most extraordinary developments both in clinical medicine and in the medical device industry over the past 30 years has been the birth and growth of interventional cardiology. IN VIVO remembers Donald Baim, one of the pioneers of the field, who died on November 6, 2009 at the age of 60.

Biopharma Trends: Nowhere To Go But Up (IN VIVO)

IN VIVO

Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. VCs hunkered down as capital and exits remained scarce, and pharmaceutical acquirers remained cautious.Those deals that did get done were typically structured affairs or options-to-deal. In addition, health care reform added to the ongoing drama and uncertainty

Pay-for-Performance in the US: What Could Work, What Won't (IN VIVO)

IN VIVO

In theory, pay-for-performance (P4P) contracts could be highly desirable tools to address shifting dynamics of the pharma market, but, in practice, they�re likely to remain rare because they�re expensive and complicated to implement. Two recent, high-profile collaborations between pharma companies and payors in the US highlight growing interest in P4P arrangements, but experts are divided over whether they can be widely emulated.

Has Orthovita's Fight Finally Ended? (IN VIVO)

IN VIVO

Orthovita had spent the past eight years building up a small commercial pipeline while it ran its flagship bone augmentation material Cortoss through years of a demanding clinical trial. But two months after the FDA approved the product, the company had to clear another unforeseen hurdle: two controversial clinical trials.

Flexion Exploits Big Pharma as Discovery Supplier (IN VIVO)

IN VIVO

Big Pharma, unable to exploit its own research productivity, is increasingly seeing itself as a supplier of discovery assets. That's bad news for discovery-based biotech, but good news for companies with a talent for faster, more predictable development capabilities. Since its formation in the fall of 2007, Flexion Therapeutics has apparently had no trouble getting Big Pharmas to let them review their shelved compounds, 130 or so of them from eight to 10 companies. Flexion, built around Lilly's fast-to-proof-of-concept strategy, is attempting to take advantage of the trend; it's in-licensed five products from three Big Pharmas.

How Bayer Secured the Top-Spot in China: An Interview with Liam Condon (IN VIVO)

IN VIVO

A focus on older, primary care brands--initially running contrary to Bayer Schering's group strategy post-merger--was key to the company's reaching its leadership position in China. Liam Condon, Managing Director of Bayer HealthCare China, talks about the group's commercial success to date and its future plans, particularly to build up its R&D presence.

The Art of the Deal: Device M&A in Difficult Times (IN VIVO)

IN VIVO

Advanced Medical Optics, Ablation Frontiers, Acclarent, CoreValve, Evalve, Visiogen.-no tip of the iceberg last year; they were just about the whole berg in medical device M&A. Starting with AMO last January and ending with Acclarent in December it would be easy to look at the series of impressive device acquisitions that took place last year and be lulled into the belief that 2009 was a banner year for medical device M&A. In fact, just the opposite was true: total deal values and numbers were at their lowest peak in more than half a decade. What does it take to get a company sold these days? To look more closely at the topic, we asked some folks who've recently been on either side of a deal to talk, not so much about the current state of deal-making, but about how successful deals come about in today's environment.

Selected Start-Ups (01/2010) (IN VIVO)

IN VIVO

In Vivo briefly describes these recently founded companies: Acton Pharmaceuticals, AesRx, Lungpacer Medical, MAX Endoscopy, OtoKinetics and Thermalin Diabetes.

Start-Up Previews (01/2010) (IN VIVO)

IN VIVO

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target the GI Tract," features profiles of Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences. Plus these Start-Ups Across Health Care: Advanced Cardiac Therapeutics, Concert Pharmaceuticals, ImThera Medical, On-Q-ity and Telormedix.

Deals Shaping the Medical Industry (01/2010) (IN VIVO)

IN VIVO

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

On the Move (Company Changes and Promotions 01/2010) (IN VIVO)

IN VIVO

Recent executive-level company changes and promotions in the biotech, pharmaceutical, and medical device industries.

2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups (Start-Up)

Start-Up

Not every acquisition of a venture-backed biotech in 2009 was a structured deal that included earn-outs based on clinical or regulatory milestones. But it sure was close. Thirteen private biotechnology companies were acquired in 2009 and of those deals only a few did not include contingent value rights (CVRs).

The Merger/License Dance of AstraZeneca, Forest and Novexel (Start-Up)

Start-Up

As public health officials warn about new strains of resistant bacteria spreading in hospitals, drug firms have been slow to produce new ammunition. But the past few years have seen a spate of deals, both licenses and acquisitions, among firms maneuvering into the antibiotic space. The latest antibiotic deal-AstraZeneca PLC's two-step, $350 million acquisition of Novexel SA--happened just before the winter holidays and was easy to overlook amid the year-end flurry of industry action. It's worth revisiting for a few reasons.

Is there a Market for Wireless Cardiac Monitoring Implants? (Start-Up)

Start-Up

Transoma, which was developing an implantable ECG monitor for continuous, wireless arrhythmia monitoring closed its doors in December. Before that, Medtronic failed to gain FDA approval for an implantable hemodynamic monitor for heart failure. That's two strikes; what will it take for companies with implants for wireless monitoring to stay in the game? Jay Yadav, MD, of CardioMEMS gives his opinion.

Computer-Aided Detection: Bad Year, Bright Future (Start-Up)

Start-Up

For the manufacturers of computer-aided detection products, 2009 was not a good year. For the industry as a whole, revenues dropped 10%, according to "US Markets for Computer-Aided Diagnostic Imaging Products," a report recently issued by the Medtech Insight division of Elsevier Business Intelligence. This was largely due to the economic recession, cost pressures faced by hospitals, and a subsequent squeeze on capital equipment-related products. But for the foreseeable future, the industry is expected to grow at a compound annual rate of 11.1% to reach an estimated $185.3 million by the years 2013.

Best of the IN VIVO Blog, (01/2010) (Start-Up)

Start-Up

Some of our favorite blog posts about topics not covered elsewhere in this issue of Start-Up. (See the original postings for free at http://invivoblog.blogspot.com/).

The A-List: 2009's Trend-Shaping Series A Financings (Start-Up)

Start-Up

New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.

Next-Generation Coronary Stent Start-Ups: Making a Difference in a Mature Market (Start-Up)

Start-Up

Which kinds of innovations make for incremental enhancements in the hands of large companies and which are meaningful enough to sustain a venture-backed start-up company? In a mature market for coronary stents dominated by large companies, start-ups developing new stents need to find the answers. Areas of innovation fall into four basic categories: improving stent safety and biocompatibility, avoiding the need for dual antiplatelet therapy, enhancing deliverability, and introducing specialty stents for complex vessels. Three companies profiled here have a plan for taking sufficient market share, reducing risk, and rewarding investors.

Biotechs Target the GI Tract (Start-Up)

Start-Up

Regulatory risk and a mature market for some indications have driven Big Pharma players from the gastrointestinal space. That signals possible biotech opportunity. In this issue, we profile Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences.

Alvine Pharmaceuticals Inc. (Start-Up)

Start-Up

Alvine Pharmaceuticals aims to treat celiac disease-a common hereditary autoimmune disorder in which the intestinal lining reacts to wheat, barley or rye gluten, leading to pain, bloating, and damage to the gut--with an orally available drug meant to degrade gluten in the stomach into peptide fragments too small to stimulate an immune response. Generally, antigens need to be at least nine amino acids long to rouse an immune response, but Alvine expects its lead compound to chop up gluten into peptide fragments a third that size or smaller.

Genetic Analysis AS (Start-Up)

Start-Up

A number of diseases are associated with or influenced by imbalances in gut bacteria, including autism and GI disorders such as ulcers, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, colon cancer, and necrotizing enterocolitis in preterm infants. Many other conditions not obviously associated with the gastrointestinal tract also seem to be influenced by imbalance in the gut, such as allergies, eczema, depression and obesity. Genetic Analysis is developing the G-MAP, a microbiota array technology that analyzes and profiles the gut microflora and associates the resulting profile with various diseases.

Meritage Pharma Inc. (Start-Up)

Start-Up

Meritage Pharma was built by serial biotech entrepreneur Cam Garner around a viscous formulation of budesonide designed to coat the inflamed throat. It is now in Phase II trials for an orphan indication, pediatric eosinophilic esophagitis, an inflammation of the esophagus that appears to be triggered by allergies. Meritage's decision to reformulate a compound with a well-established safety record is, like the choice to pursue an orphan drug designation, a risk- and cost-reducing maneuver that has helped other biotech companies achieve success.

Ventrus Biosciences Inc. (Start-Up)

Start-Up

Like other start-up companies working to develop drugs for GI disorders, Ventrus Biosciences was attracted to the sector not only by unmet clinical needs and the focused sales opportunities, but also by the potential for creating a cross-over success: a drug that launches as a prescription product but eventually leaps over the counter to become a blockbuster, � la Claritin. Ventrus has two drug candidates ready for Phase III testing: a topical gel formulation of diltiazem, a generic vasodilator, as a treatment for anal fissures, and a novel compound it hopes will become the first new product approved for hemorrhoids in 30 years.

Advanced Cardiac Therapeutics Inc. (Start-Up)

Start-Up

For more than 20 years, cardiac ablation catheter development has focused on two major areas: three-dimensional mapping systems to determine a specific patient's heart dimensions to help map arrhythmias and guide catheters, and mechanisms for catheter positioning and steerability. Little attention has been devoted to ablation lesion success and safety assessment. Advanced Cardiac Therapeutics Inc. aims to fill this gap with its intelligent, in-tissue, temperature-sensing irrigated ablation catheter. The device features a chip-based radiometry system to provide physicians with real-time in-tissue temperature when performing irrigated cardiac ablations.

Concert Pharmaceuticals Inc. (Start-Up)

Start-Up

Isolated from seawater, deuterium is a naturally occurring stable isotope of hydrogen that carries an additional neutron, and it is sometimes known as "heavy hydrogen." Concert Pharmaceuticals Inc. is using the properties of deuterium to create therapeutics based on existing drugs. Adding it to a compound can modify metabolism and create new applications and intellectual property, which Concert feels will enable it to develop highly differentiated medicines more quickly and at lower risk of failure. The company's lead candidate, the HIV protease inhibitor CTP-518, is a deuterium-modified version of Bristol-Myers Squibb's atazanavir.

ImThera Medical Inc. (Start-Up)

Start-Up

Although more than 20 million people in the US are affected by obstructive sleep apnea (OSA), the standard of care for the disorder--a continuous positive airway pressure (CPAP) machine applied at bedtime with a nasal or facial mask to keep airways propped open--carries a noncompliance rate of almost 50%. ImThera Medical Inc. is developing a new implantable neurostimulation device that stimulates certain tongue muscles during sleep to open the upper airway and potentially help patients who are unable or unwilling to use CPAP or pursue surgical alternatives.

On-Q-ity Inc. (Start-Up)

Start-Up

Formed by the 2009 merger of CELLective DX and DNA Repair Co., On-Q-ity Inc. is developing personalized molecular diagnostics for cancer. The start-up thinks that combining DNA repair biomarkers with its ability to capture and analyze circulating tumor cells provides a complete view of an individual patient's pending treatment options and allows for more patient-friendly monitoring of the treatment's progress. On-Q-ity is currently conducting large-scale trials analyzing the response of DNA repair mechanisms to breast cancer therapies, focusing particularly on the anthracycline class of drugs. Initial studies are based on tissue samples, but the company will begin trials with circulating tumor cells in various cancers later this year.

Telormedix SA (Start-Up)

Start-Up

Swiss-based Telormedix is developing small-molecule drugs for cancer and auto-immune disease, harnessing the innate immune system--and toll-like receptor 7 (TLR-7) in particular.

Emergings in Brief (01/2010) (Start-Up)

Start-Up

Brief profiles of these recently formed companies: Lungpacer Medical, OtoKinetics, Thermalin Diabetes and Vortex Biotechnology.

Light-Driven Molecular Nanomachines to Treat Pain and Neurodegenerative Disorders (Start-Up)

Start-Up

Imagine exposing a person to a particular wavelength of light and having a predetermined species of neuron shut down for as long as that light is on. Then a second light comes in to turn another neuron off, or turn one on, and so on. That's what an emerging group of researchers and a couple of start-up companies hope to be able to do, to potentially treat a variety of neurological conditions from chronic pain to seizures to spinal cord injury and even eye diseases.

On the Move: Who's Going Where in Biopharma and Medtech Start-Ups (01/2010) (Start-Up)

Start-Up

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

Recent Financings of Private Companies (01/2010) (Start-Up)

Start-Up

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

Recent Tech Transfer Deals (01/2010) (Start-Up)

Start-Up

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.

Public Interest/Private Sector: Perspectives on Conflict of Interest (The RPM Report)

The RPM Report

Conflict of interest remains a thorny topic in the conduct, analysis and dissemination of clinical trials. Four panelists on a recent Windhover Webinar offer their perspectives on how private companies can best align with the public interest goals of medical research.

Antibiotic Susceptibilty Re-labeling Increases FDA Susceptibility To New Political Challenges (The RPM Report)

The RPM Report

The FDA faces a difficult, legislatively-mandated requirement in the anti-infective area. It is charged with updating antibioitic susceptibility charts in labeling for all approved anti-infectives. That is a huge task -- almost equivalent to re-reviewing the large cadre of existing antibiotic drugs. To try to achieve the task, the agency has proposed trusting an outside standards group for help. That sounds like a practical solution; but Capitol Hill has political problems.

The Year of the Unpartnered Blockbuster? High Profile Applications Raise Big Questions (The RPM Report)

The RPM Report

Several of the highest profile new drug applications pending or expected to be submitted as 2010 begins involve potential blockbuster market opportunities. They also lack Big Pharma partners. Is Big Pharma really that picky? Or are the applications out of step with the regulatory and commercial climate? Either way, intense investor interest will keep FDA in the spotlight.

Free Speech Jan. 2010 (The RPM Report)

The RPM Report

Government and industry leaders discuss follow-on biologics, reverse payments and health care refrom.

Health Reform in the Balance: What It Means for Biopharma (The RPM Report)

The RPM Report

The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach.

The Triumph of Part D (The RPM Report)

The RPM Report

The US prescription drug market remains anemic, but don't blame the federal government. The Medicare Prescription Drug Benefit that began in 2006 is the only reason there has been any growth in the retail sector. No wonder industry is so eager for health care reform.

No Fault? Not Quite (The RPM Report)

The RPM Report

An HHS departmental appeals board decision finds Purdue executives at fault despite plea and convictions based solely on the Dotterweich and Park doctrines

Opening Up the Black Box: FDA Wants To Make "Complete Response" Letters Public (The RPM Report)

The RPM Report

FDA's transparency initiative is starting to take shape. While many industry executives see the value in making more information available to the public, one idea makes them nervous: publicizing the letters FDA sends when it declines to approve a new drug or biologic. Top FDA officials already support making "complete response" letters public, and the Commissioner's office is open to the idea. How should industry prepare?

Clinical Edge (Medtech Insight)

Medtech Insight

Brief summaries of recent advances in device research and clinical trials, including a neural interface for prosthetic limbs, new tools to detect cancer, and results of a multicenter study of the costs of treating MRSA.

AAO Highlights: Back (of the Eye) to the Future (Medtech Insight)

Medtech Insight

The 2009 meeting of the American Academy of Ophthalmology showcased the latest developments in cataract/refractive surgery, glaucoma, retina, and other ophthalmic subspecialties. The cataract/refractive surgery market has been under significant economic pressure recently due to a recessionary drop in elective ophthalmic procedures. However, evolving treatments for "back of the eye" conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy, are making significant inroads toward improved patient outcomes for these common and devastating diseases and continue to energize the retina products market.

Injectable Solutions for Joint and Back Pain (Medtech Insight)

Medtech Insight

Injectable products that can alleviate pain and even reverse the disease process are on the horizon for treating degenerative orthopedic and spinal conditions, such as damaged articular joint cartilage and deteriorated spinal discs. With no available long-term treatment options for these conditions short of invasive surgical procedures like joint replacement or spinal fusion, injectable technologies that offer the possibility of being used upstream in the continuum of care are potential billion-dollar market opportunities. In fact, in a post health care reform environment, injectable therapies may prove to be the most cost-effective way for treating many degenerative conditions.

The Future of Drug-Eluting Stents Part II: Biodegradable Platforms (Medtech Insight)

Medtech Insight

The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. However, many researchers in this field believe the future of stenting will be defined by completely biodegradable stents that do their job of propping open the vessel until healing occurs, and gradually degrade over a period of months or years, leaving nothing permanently behind in the vessel.

Technology for Paralysis Outpaces Funding (Medtech Insight)

Medtech Insight

Among the biggest challenges in medical technology is the search for therapies to help patients regain body function after suffering a paralyzing spinal cord injury. Research in this area is producing some very promising theories and applications that eventually could lead to substantial breakthroughs. Teams of doctors and scientists continue to work diligently in what can be described as a dedicated, niche market, where the driving force is tied to the very basic medical goal of improving these patients' quality of life.

Physicians and Industry Respond to Recent Vertebroplasty Studies (Medtech Insight)

Medtech Insight

In August 2009, vertebral compression fracture treatment was dealt an unexpected blow when The New England Journal of Medicine published two articles that detailed prospective randomized controlled trials in which vertebroplasty did not result in a statistically significant clinical benefit over a sham procedure. The spinal community responded quickly to these articles, pointing out shortcomings of the two trials.

Providers Flex Clout for Product Identification Standards (Medtech Insight)

Medtech Insight

The push for more efficient, cost effective ways to provide health care is a never-ending vigil filled with inherent complications and obstacles to success. However, on close examination, it becomes apparent it is not for lack of good ideas and techniques that improvement efforts are hampered, but rather a lack of uniform clout to force the wide assortment of vested players to come together and agree on a single solution. This has been a chief impediment in preventing the health care supply chain from realizing a standardized product identification system--until now.

Market & Industry Briefs (Medtech Insight)

Medtech Insight

Brief summaries of recent medtech market and industry developments. This month we cover refractive surgery highlights from AAO, Novartis' takeover of Alcon, and DOJ's increased interest in device manufacturing and safety issues.

Deals Update (Medtech Insight)

Medtech Insight

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

Start-Up News (Medtech Insight)

Medtech Insight

Noteworthy news from medtech start-ups. This month we profile Epicardial Technologies Inc., which is developing technology for percutaneous epicardial ablation of heart arrhythmias, Svelte Medical's technology for enhancing stent deliverability, Bioring's biodegradable annuloplasty ring and Advanced BioSensor's second-generation glucose monitoring device.

Windhover's Commentary

Deals in Depth: November 2009 (IN VIVO)

2009's Top Biopharma Dealmakers (IN VIVO)

Novartis Eyes Full, $50 billion Alcon Takeover (IN VIVO)

Sanofi Builds US-based Consumer Powerhouse in Preparation for Allegra OTC Switch (IN VIVO)

Remembering Donald Baim (IN VIVO)

Biopharma Trends: Nowhere To Go But Up (IN VIVO)

Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk (IN VIVO)

Top Device Stories of the Decade (IN VIVO)

Pay-for-Performance in the US: What Could Work, What Won't (IN VIVO)

Has Orthovita's Fight Finally Ended? (IN VIVO)

Flexion Exploits Big Pharma as Discovery Supplier (IN VIVO)

How Bayer Secured the Top-Spot in China: An Interview with Liam Condon (IN VIVO)

The Art of the Deal: Device M&A in Difficult Times (IN VIVO)

Selected Start-Ups (01/2010) (IN VIVO)

Start-Up Previews (01/2010) (IN VIVO)

Deals Shaping the Medical Industry (01/2010) (IN VIVO)

On the Move (Company Changes and Promotions 01/2010) (IN VIVO)

2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups (Start-Up)

The Merger/License Dance of AstraZeneca, Forest and Novexel (Start-Up)

Is there a Market for Wireless Cardiac Monitoring Implants? (Start-Up)

Computer-Aided Detection: Bad Year, Bright Future (Start-Up)

Best of the IN VIVO Blog, (01/2010) (Start-Up)

The A-List: 2009's Trend-Shaping Series A Financings (Start-Up)

Next-Generation Coronary Stent Start-Ups: Making a Difference in a Mature Market (Start-Up)

Biotechs Target the GI Tract (Start-Up)

Alvine Pharmaceuticals Inc. (Start-Up)

Genetic Analysis AS (Start-Up)

Meritage Pharma Inc. (Start-Up)

Ventrus Biosciences Inc. (Start-Up)

Advanced Cardiac Therapeutics Inc. (Start-Up)

Concert Pharmaceuticals Inc. (Start-Up)

ImThera Medical Inc. (Start-Up)

On-Q-ity Inc. (Start-Up)

Telormedix SA (Start-Up)

Emergings in Brief (01/2010) (Start-Up)

Light-Driven Molecular Nanomachines to Treat Pain and Neurodegenerative Disorders (Start-Up)

On the Move: Who's Going Where in Biopharma and Medtech Start-Ups (01/2010) (Start-Up)

Recent Financings of Private Companies (01/2010) (Start-Up)

Recent Tech Transfer Deals (01/2010) (Start-Up)

Public Interest/Private Sector: Perspectives on Conflict of Interest (The RPM Report)

Antibiotic Susceptibilty Re-labeling Increases FDA Susceptibility To New Political Challenges (The RPM Report)

The Year of the Unpartnered Blockbuster? High Profile Applications Raise Big Questions (The RPM Report)

Free Speech Jan. 2010 (The RPM Report)

Health Reform in the Balance: What It Means for Biopharma (The RPM Report)

The Triumph of Part D (The RPM Report)

No Fault? Not Quite (The RPM Report)

Opening Up the Black Box: FDA Wants To Make "Complete Response" Letters Public (The RPM Report)

Clinical Edge (Medtech Insight)

AAO Highlights: Back (of the Eye) to the Future (Medtech Insight)

Injectable Solutions for Joint and Back Pain (Medtech Insight)

The Future of Drug-Eluting Stents Part II: Biodegradable Platforms (Medtech Insight)

Technology for Paralysis Outpaces Funding (Medtech Insight)

Physicians and Industry Respond to Recent Vertebroplasty Studies (Medtech Insight)

Providers Flex Clout for Product Identification Standards (Medtech Insight)

Market & Industry Briefs (Medtech Insight)

Deals Update (Medtech Insight)

Start-Up News (Medtech Insight)